Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
- None.
- None.
Insights
The notice of allowance for Vanda Pharmaceuticals' patent application for PONVORY® represents a significant strengthening of the company's intellectual property portfolio. This is crucial in the pharmaceutical industry where patents are a key determinant of a company's ability to secure exclusive market rights and recoup R&D investments. The extension of this patent until 2042 provides a longer runway for Vanda to capitalize on PONVORY® without facing generic competition, which typically drives down prices and market share. This move could potentially lead to increased revenue projections and market exclusivity for an extended period, which investors might view favorably.
From a competitive standpoint, the listing of the patent in the FDA's Orange Book is a strategic action that signals to potential generic competitors that they will face legal barriers if they attempt to enter the market with a similar product before the patent expires. This could deter early generic entry, maintaining Vanda's pricing power and market share. The patent covers not only the composition of the drug but also methods for reducing clinical management events and reinitiating treatment, which may provide additional layers of protection against workarounds by competitors.
The approval and patent protection of PONVORY® in the treatment of multiple sclerosis (MS) tap into a significant market, given the chronic nature of MS and the need for ongoing treatment. The prevalence of MS and the demand for effective therapies can drive the market potential for PONVORY®. The fact that PONVORY® is approved for multiple forms of relapsing MS, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, indicates a broad target population, which could translate to higher sales volumes.
Moreover, the acquisition of rights from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company, suggests a strategic collaboration that could leverage Janssen's established market presence and expertise in the field. It's important to analyze market share dynamics, payer coverage and the competitive landscape, including how PONVORY® differentiates itself from other MS treatments in terms of efficacy, safety and patient convenience, as these factors will influence its commercial success.
The therapeutic relevance of PONVORY® in the MS treatment space is underscored by its FDA approval for a spectrum of relapsing conditions. The patent's coverage of methods for reducing clinical management events is indicative of a potential improvement in treatment protocols, which may enhance patient adherence and outcomes. Missed doses in chronic diseases like MS can lead to exacerbation of symptoms or relapse, so a patented method for reinitiating treatment could represent a significant advantage in clinical practice.
It's essential to consider the clinical implications of these patented methods on patient care and how they might influence physician prescribing behavior. If these methods are shown to reduce hospitalizations or other costly clinical events, this could not only benefit patients but also create economic value for healthcare systems and insurers. This, in turn, could affect the drug's adoption rate and market penetration, impacting Vanda's financial performance and attractiveness to investors.
Vanda acquired rights to
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
About PONVORY®
PONVORY® (ponesimod) is a daily oral selective sphingosine-1-phosphate receptor 1 (S1P1R) modulator, indicated to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY® blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. PONVORY® does not require genetic testing or first-dose cardiac monitoring for most patients. Because initiation of PONVORY® treatment results in a decrease in heart rate, first-dose monitoring is recommended in patients with certain preexisting cardiac conditions. For full
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS) in which immune cells attack myelin (the protective casing that insulates nerve cells), damaging or destroying it and causing inflammation. This affects how the CNS processes information and communicates with the rest of the body, causing the neurologic signs and symptoms of MS. Symptoms vary by person, but common symptoms include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo, vision problems, bladder and bowel problems and weakness.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this press release, including, but not limited to statements regarding the USPTO's plans to issue the new PONVORY® patent, the anticipated life of the patent and Vanda's intentions to list the patent in the Orange Book, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the payment by Vanda to the USPTO of all fees required prior to the issuance of the patent, the ultimate issuance of the patent by the USPTO and Vanda's ability to protect its intellectual property rights and defend the new PONVORY® patent against any attempt to invalidate it. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-a-us-patent-allowance-for-ponvory-ponesimod-in-the-us-302045334.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
What is the notice of allowance Vanda Pharmaceuticals received?
What is the patent application number for PONVORY®?
What is the expected expiration date for the patent?
What is PONVORY® approved for?
Who did Vanda Pharmaceuticals acquire rights to PONVORY® from?
